Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 17/20 | 0.88 |
| ▸ | PDGFRA | P16234 | 17/20 | 0.88 |
| ▸ | EGFR | P00533 | 1/20 | 0.88 |
| ▸ | INSR | P06213 | 1/20 | 0.88 |
| ▸ | LCK | P06239 | 1/20 | 0.88 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3886006 | 1.00 | PDGFRB (0.88) | PDGFRBPDGFRAEGFRINSRLCK | |
| Sulfuric Acid SCHEMBL2788130 | 1.00 | PDGFRB (0.88) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL3393843 | 0.94 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL842647 | 0.94 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL6896442 | 0.93 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| Hydrochloric Acid SCHEMBL7872629 | 0.93 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL6896444 | 0.93 | PDGFRB (0.97) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL29729307 | 0.86 | PDGFRB (0.69) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL20704099 | 0.86 | PDGFRB (0.69) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL1401265 | 0.86 | PDGFRB (0.84) | PDGFRBPDGFRAEGFRINSRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001946-B1 | QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2010-12-29 | — | — | EP | claimed |
| EP-3661539-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of The University of California (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-111246873-A | Optimized peptides for targeting human nerves and their use in image-guided surgery, diagnosis and therapy delivery | 加利福尼亚大学董事会 | 2020-06-05 | — | — | CN | disclosed |
| WO-2019028281-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-07 | — | — | WO | disclosed |
| US-10092580-B2 | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9072773-B2 | Compositions for labeling nerves and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130202537-A1 | COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE | AVELAS BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120134931-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| EP-1687642-B1 | Screening methods for combinations of biological compounds | CENTELION (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| EP-1687642-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005038465-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | PDGFRB 3469/4885PDGFRA 4041/4885EGFR 1868/4885 |
| US-10092580-B2 | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTC, TLR3, STING1 | PDGFRB 2259/4885PDGFRA 2908/4885EGFR 1547/4885 |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | MCL1, ABL1, TIE1 | PDGFRB 13/4885PDGFRA 10/4885EGFR 116/4885 |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, TLR3, STING1 | PDGFRB 2259/4885PDGFRA 2908/4885EGFR 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.